Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of NT-501 for Macular Telangiectasia Type 2
NCT03071965Phase 2Completed
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- May 2017
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Device-based Delivery
- Countries
- 2
01
Overview
A Phase 2 trial of revakinagene taroretcel-lwey in macular telangiectasia type 2 (MacTel), sponsored by Neurotech Pharmaceuticals, Inc.. Started May 2017; status: completed.
02
Drugs
revakinagene taroretcel-lwey
03
Conditions
macular telangiectasia type 2 (MacTel)
Beyond the preview
Go deeper on NCT03071965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071965.